GB Sciences, CEO, John Poss, Joins Everett Jolly on Uptick Newswire’s “Stock Day” Podcast

PHOENIX, April 19, 2018 -- GB Sciences, Inc. (OTCQB:GBLX) (“the “Company”), today announced CEO, John Poss, returned to Uptick Newswire’s “Stock Day” podcast with Everett Jolly for an operational update.

“GB Sciences is a cannabis based medical research company,” said Jolly.  “It has built a strong commercial brand, which helps the Company fund research.  John Poss joins us today to discuss the many things that have come to pass in recent months.”

The Company is currently in 30-day due diligence period for the acquisition of Nevada Pure. Additionally, GB Sciences is planning to file an Exploratory IND in order to initiate an in-human trial for a Parkinson’s therapy.  “We are excited for what the year will bring,” said Poss.  “We hope to have FDA approval for our Parkinson’s trail by December of this year.  The acquisition of Nevada Pure would bring about $16 million to our bottom line and we have until April 26^th to finalize the purchase; in all we are excited about 2018.”

To listen to the full interview please click here to the following link: https://upticknewswire.com/featured-interview-ceo-john-poss-of-gb-sciences-inc-otcqb-gblx-4/

About GB Sciences, Inc.
GB Sciences, Inc. (OTCQB:GBLX) is a diverse cannabis company, focused on standardized cultivation and production methods; as well as biopharmaceutical research and development. The Company’s goal is creating safe, standardized, pharmaceutical-grade, cannabinoid therapies that target a variety of medical conditions. To learn more about GB Sciences, Inc., go to: http://gbsciences.com.

Forward-Looking Statements
This press release may contain statements relating to future results or events, which are forward-looking statements.  Words such as “expects”, “intends”, “plans”, “may”, “could”, “should”, “anticipates”, “likely”, “believes” and words of similar import may identify forward-looking statements. These statements are not historical facts, but instead represent only the Company’s belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company’s control.  It is possible that the Company’s actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements.  Further, information concerning the Company and its business, including factors that potentially could materially affect the Company’s business and financial and other results, are contained in the Company’s filings with the Securities and Exchange Commission, available at www.sec.gov.  All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.

Note:  Although the Company’s research and development activities are not illegal, the production and sale of cannabis products violate federal laws as they presently exist.

Contact Information
Corporate:

GB Sciences, Inc., 3550 West Teco Ave., Las Vegas, NV 89118

866-721-0297, or

Tom Arcuragi, EVP, [email protected]

About Uptick Newswire and the “Stock Day Podcast”
Uptick Newswire is a private company reaching out to the masses keeping investors and shareholders up to date on company news and bringing transparency to the undervalued, undersold, micro-cap stocks of the market and is the sole producer of the Uptick Network “Stock Day” Podcast. The Uptick Network “Stock Day” Podcast is an extension of Uptick Newswire and has recently launched the Video Interview Studio located in Phoenix, Arizona with its new host Kathryn Donnelly.

Investors Hangout is a proud sponsor of Stock Day and Uptick Newswire encourages listeners to visit BioLargo, Inc., message board on: https://investorshangout.com/